By Josh Beckerman
Zoetis said the U.S. Department of Agriculture's Center for Veterinary Biologics issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus.
The vaccine is labeled for use in chickens, the company said.
The USDA's Animal and Plant Health Inspection Service said Jan. 8 it would pursue a vaccine stockpile that matches current outbreak strains. In 2016, USDA created a vaccine stockpile for use in commercial poultry, though the vaccines at that time were never deployed. Zoetis received a contract award for the 2016 stockpile.
On Friday, Zoetis said that when a new strain was identified in the U.S. in early 2022, it immediately began work to update its previous vaccine.
The company's major products include Simparica, a chewable tablet for dogs that protects against ticks and fleas. In 2024, livestock revenue was about $2.9 billion out of $9.26 billion overall.
In January, Moderna announced that a $590 million government award to support development of bird flu vaccines.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 14, 2025 14:16 ET (19:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.